Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

2021342 citationsJournal Articlehybrid Open Access

Authors

Feng‐Hua Wang · Sun Yat-sen University

Xiaoli Wei · Sun Yat-sen University

Jifeng Feng · Jiangsu Cancer Hospital

Qi Li · Shanghai Jiao Tong University

Nong Xu · First Affiliated Hospital Zhejiang University

Xichun Hu · Fudan University Shanghai Cancer Center

Wangjun Liao ·

Abstract

The POLARIS-02 study demonstrated a manageable safety profile and durable clinical response of toripalimab in patients with chemorefractory metastatic NPC. An early decrease in plasma EBV DNA copy number correlated with favorable response.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 7, pp. 704-712

DOI: 10.1200/jco.20.02712

Field-Weighted Citation Impact: 22.55